Top

Cancer Chemotherapy and Pharmacology

Published in:

01-02-2017 | Review Article

The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer

Authors: Hongjing Zang, Weiyuan Wang, Songqing Fan

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2017

Abstract

Purpose

Non-small cell lung cancer (NSCLC), accounting for the most of lung cancers, is usually diagnosed in advanced stage. Targeted treatments boost advanced NSCLC patients with certain mutations, but early drug resistance blocks the advantages of target medicine. MicroRNAs (miRNAs) are regarded as a cluster of small noncoding and posttranscriptionally negative regulating RNAs. We want to explore the role of miRNAs in resistance to targeted treatments of NSCLC to improve the prognosis.

Methods

We reviewed recent studies about miRNAs and targeted treatment resistance in NSCLC and classified resistance into two types: EGFR-TKIs resistance and ALK-TKIs resistance.

Results and conclusion

Recent studies indicate that miRNAs involve in drug resistance possession in positive and negative manners. Inhibiting expression of certain miRNAs that promote drug resistance and increasing expression of miRNAs that reverse drug resistance may illuminate novel prospect of adjuvant targeted treatments in NSCLC.

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297CrossRefPubMed

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed

García-Campelo R, Bernabé R, Cobo M, Corral J, Coves J, Dómine M, Nadal E, Rodriguez-Abreu D, Viñolas N, Massuti B (2015) SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. Clin Transl Oncol 17(12):1020–1029CrossRefPubMedPubMedCentral

Bastid J (2012) EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev 31(1–2):277–283CrossRefPubMed

Scheel C, Weinberg RA (2011) Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer 129(10):2310–2314CrossRefPubMedPubMedCentral

Xiaofeng Z, Carstens JL, Jiha K, Matthew S, Judith K, Hikaru S, Chia-Chin W, Lebleu VS, Raghu K (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527(7579):525–530CrossRef

Fischer KR, Anna D, Sharrell L, Jianting S, Fuhai L, Wong STC, Hyejin C, Tina ER, Seongho R, Juliane T (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527(7579):472–476CrossRefPubMedPubMedCentral

Jean Paul T, Sleeman JP (2006) Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142CrossRef

Jiri Z, Böttinger EP (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24(37):5764–5774CrossRef

10.

Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A (2014) MiR-134/487b/655 cluster regulates TGF-β-induced epithelial–mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 13(2):444–453CrossRefPubMed

11.

Mengru C, Masahiro S, Chie S, Hideaki M, Kazuhiro K, Yuji M, Rintaro N, Akinobu Y, Li C, Akihiko G (2012) MiR-23a regulates TGF-β-induced epithelial–mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol 41(3):869–875

12.

Engelman JA, Kreshnik Z, Tetsuya M, Youngchul S, Courtney H, Joon OhP, Neal L, Christopher-Michael G, Xiaojun Z, James C (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043CrossRefPubMed

13.

Garofalo M, Romano G, Leva GD, Nuovo G, Jeon YJ, Ngankeu A, Jin S, Lovat F, Alder H, Condorelli G (2011) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18(1):74–82PubMedPubMedCentral

14.

Fumarola C, Bonelli MA, Petronini PG, Alfieri RR (2014) Targeting PI3 K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol 90(3):197–207CrossRefPubMed

15.

Vassiliki P (2012) Development of PI3 K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 7(8):1315–1326

16.

Balsara BR, Jianming P, Yasuhiro M, Robert P, Andres KS, Hao W, Michael U, Testa JR (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25(11):2053–2059CrossRefPubMed

17.

Stefano V, Calin GA, Chang-Gong L, Stefan A, Amelia C, Fabio P, Rosa V, Marilena I, Claudia R, Manuela F (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257–2261CrossRef

18.

Jinsong L, Hongzhang H, Lijuan S, Mei Y, Chaobin P, Weiliang C, Donghui W, Zhaoyu L, Chunxian Z, Yandan Y (2009) MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res Off J Am Assoc Cancer Res 15(12):3998–4008CrossRef

19.

Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G (2010) Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 5(5):65CrossRef

20.

Zadeh MM, Motamed N, Ranji N, Majidi M, Falahi F (2016) Silibinin-Induced apoptosis and downregulation of MicroRNA-21 and MicroRNA-155 in MCF-7 human breast cancer cells. J Breast Cancer 19(1):45–52CrossRefPubMedPubMedCentral

21.

Bing L, Shengxiang R, Xuefei L, Yongsheng W, David G, Songwen Z, Xiaoxia C, Chunxia S, Mo C, Peng K (2013) MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer 83(2):146–153

22.

Matia-Merino L, Singh H (2014) Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS ONE 9(7):e103305CrossRef

23.

Jian-Ya Z, Xi C, Jing Z, Zhang B, Xing C, Pei Z, Zhen-Feng L, Jian-Ying Z (2014) MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett 351(2):265–271CrossRef

24.

Gong LC, Susan MC, Mike G, Cindy T, Yeatman TJ (2014) MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. PLoS ONE 9(1):e84597CrossRef

25.

Elisa B, Sholl LM, Michael P, John R, Christopher W, Lenora D, Natalie V, Dyane B, Yeap BY, Michelangelo F (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177(1):415–423CrossRef

26.

Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, Digiovanna MP, Stern DF (2009) Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 100(6):941–949CrossRefPubMedPubMedCentral

27.

Zhen Q, Liu J, Gao L, Liu J, Wang R, Chu W, Zhang Y, Tan G, Zhao X, Lv B (2015) MicroRNA-200a targets EGFR and c-Met to inhibit migration, invasion, and gefitinib resistance in non-small cell lung cancer. Cytogenet Genome Res 129(10):2310–2314

28.

Ge X, Zheng L, Huang M, Wang Y, Bi F (2014) MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells. Mol Med Rep 11(1):333–340PubMed

29.

Gao Y, Fan XW, Li WN, Ping W, Deng Y, Fu XN (2014) miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem Biophys Res Commun 446(1):179–186CrossRefPubMed

30.

Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18(5):1472–1482CrossRefPubMedPubMedCentral

31.

Shaw AT, Dong-Wan K, Kazuhiko N, Takashi S, Lucio C, Myung-Ju A, Tommaso DP, Benjamin B, Solomon BJ, Fiona B (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394CrossRefPubMed

32.

Choi YL, Soda M, Yamashita Y et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18):1734–1739CrossRefPubMed

33.

Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18(5):1472–1482CrossRef

34.

Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 4(120):1409CrossRef

35.

Dejean E, Renalier MH, Foisseau M, Agirre X, Joseph N, Paiva GR, De Saati T, Soulier J, Desjobert C, Lamant L (2011) Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia Off J Leuk Soc Am Leuk Res Fund UK 25(12):1882–1890CrossRef

36.

Cécile D, Marie-Hélène R, Julie B, Emilie D, Nicole J, Anna K, Jean S, Estelle E, Fabienne M, Jérome C (2011) MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood 117(24):6627–6637CrossRef

37.

Hironori M, Suzuki HI, Hikaru N, Masaaki N, Takashi Y, Norio K, Hiroyuki M, Koichi S, Kohei M (2011) miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 118(26):6881–6892CrossRef

38.

Olaf M, Frank H, Daniela L, Eveline S, Zlatko T, Marcel S, Gerda E, Hassler MR, Christiane T, Ana S (2010) Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphoma. Proc Natl Acad Sci 107(37):16228–16233CrossRef

39.

Coralie HA, Thibaud V, Camille D, Cathy Q, Géraldine M, Samuel Q, Jinsong J, Salvatore S, Pierre F, Monica C (2015) Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. J Clin Investig 125(9):3505–3518CrossRef

40.

Inamura K, Ishikawa Y (2016) MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. J Clin Med. doi:10.3390/jcm5030036 PubMedPubMedCentral

Title: The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer
Authors: Hongjing Zang
Weiyuan Wang
Songqing Fan
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3130-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results and conclusion

Please log in to get access to this content

Other articles of this Issue 2/2017

Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways

Myeloprotective effects of C-type natriuretic peptide on cisplatin-induced bone marrow granulocytopenia in mice

Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect?

Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer